Zacks: Aevi Genomic Medicine, Inc. (GNMX) Given $5.17 Average Price Target by Analysts
Shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) have been assigned a consensus broker rating score of 2.50 (Hold) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has issued a buy rating on the company. Aevi Genomic Medicine’s rating score has declined by 25% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a one year consensus target price of $5.17 for the company and are expecting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned Aevi Genomic Medicine an industry rank of 233 out of 265 based on the ratings given to its competitors.
Separately, Jefferies Group reissued a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a research report on Thursday, September 28th.
An institutional investor recently raised its position in Aevi Genomic Medicine stock. Wells Fargo & Company MN raised its stake in shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) by 433.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 130,662 shares of the biotechnology company’s stock after purchasing an additional 106,178 shares during the period. Wells Fargo & Company MN owned 0.35% of Aevi Genomic Medicine worth $165,000 at the end of the most recent reporting period. 16.80% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Aevi Genomic Medicine (NASDAQ GNMX) traded up $0.01 on Friday, reaching $1.34. 68,926 shares of the company’s stock were exchanged, compared to its average volume of 191,075. The firm has a market capitalization of $78.91, a PE ratio of -1.19 and a beta of 0.40. Aevi Genomic Medicine has a one year low of $0.98 and a one year high of $6.18.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). During the same quarter last year, the business earned ($0.29) EPS. sell-side analysts forecast that Aevi Genomic Medicine will post -0.88 EPS for the current year.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.